Clinical trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
44 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic · PI: Ulrich Specks, MD
- RECRUITINGEarly Phase 1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh · PI: Neeraj Dhaun, MBChB PhD
- RECRUITINGPhase 1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPhase 2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPhase 3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute · PI: David Massicotte-Azarniouch, MD, MSc
- RECRUITINGPhase 3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd · PI: Minghui Zhao, M.D.
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
- RECRUITINGEarly Phase 1NCT07203404A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.Nanjing Bioheng Biotech Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06828042Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune DiseasesPeking University Third Hospital
- RECRUITINGPhase 1NCT06978647A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesChina Immunotech (Beijing) Biotechnology Co., Ltd.
- RECRUITINGPhase 2NCT06868290Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPANovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPhase 3NCT04871191Study of Salvage Therapy to Treat Patients with Granulomatosis with PolyangiitisAssistance Publique - Hôpitaux de Paris · PI: Benjamin Terrier, MD, PhD
- RECRUITINGPhase 1NCT06941129CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGN/ANCT06614270Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune DiseasesSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT06685042Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune DiseasesFondazione Policlinico Universitario Agostino Gemelli IRCCS · PI: Maria Antonietta D'Agostino
- RECRUITINGNCT06696027AYLo - AutoimmunitY and Loss of yUniversity of Bonn
- RECRUITINGPhase 4NCT06611696Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisChiba University · PI: Masayoshi Harigai, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT06733935A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)Nkarta, Inc. · PI: Nkarta Study Director
- RECRUITINGPhase 3NCT06321601Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.Amgen · PI: MD
- RECRUITINGEarly Phase 1NCT06548607Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune DiseasesNanjing Bioheng Biotech Co., Ltd.
- ACTIVE NOT RECRUITINGPhase 2NCT06388941Iptacopan in Patients With ANCA Associated VasculitisNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 1NCT06152172CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101David Porter
- RECRUITINGNCT06508346Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAVThe Children's Hospital of Zhejiang University School of Medicine · PI: Jianhua Mao, PhD
- RECRUITINGPHASE1, PHASE2NCT06350110Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)Essen Biotech
- RECRUITINGPhase 1NCT06308978A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseFate Therapeutics
- RECRUITINGPhase 4NCT06072482A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisAmgen · PI: MD
- RECRUITINGN/ANCT06277427Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T CellsLingli Dong · PI: Lingli Dong, MD
- RECRUITINGNCT06794827Early-access Avacopan in Real-world ANCA-associated VasculitisLeiden University Medical Center · PI: Y.K. Onno Teng
- RECRUITINGPhase 1NCT06316076Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune DiseasesRenJi Hospital
- RECRUITINGPhase 3NCT05946564A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO TrialAssistance Publique - Hôpitaux de Paris · PI: Alexandre Karras
- RECRUITINGNCT05897684Avacostar - (PASS)Vifor Fresenius Medical Care Renal Pharma
- RECRUITINGPhase 1NCT06056921Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune DiseaseChongqing Precision Biotech Co., Ltd · PI: Liyun Zhang, M.D
- RECRUITINGPhase 4NCT05962840Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)Chinese SLE Treatment And Research Group · PI: Jing Li, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05732402An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesAlpine Immune Sciences, Inc.
- RECRUITINGPhase 4NCT05965284Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)Chinese SLE Treatment And Research Group · PI: JIng Li, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT05630612ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)University of Edinburgh · PI: Neeraj Dhaun
- RECRUITINGN/ANCT05364892Biocollection of Patients With ANCA Associated VasculitisUniversity Hospital, Brest · PI: Divi CORNEC
- ACTIVE NOT RECRUITINGNCT04916704Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated VasculitisUniversity Hospital Birmingham NHS Foundation Trust · PI: Dimitrios Chanouzas, MBChB, PhD
- RECRUITINGNCT05315141Multicenter Cohort Study of AAV in Hunan of ChinaXiangya Hospital of Central South University · PI: Xiangcheng Xiao, doctor
- RECRUITINGN/ANCT03290456Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.Hospices Civils de Lyon · PI: Jean-Christophe LEGA, Pr
- ACTIVE NOT RECRUITINGPhase 3NCT03323476Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal DiseaseCentre Hospitalier Departemental Vendee · PI: Grégoire COUVRAT-DESVERGNES
- RECRUITINGNCT03004326Clinical Transcriptomics in Systemic Vasculitis (CUTIS)Peter Merkel · PI: Robert Micheletti, MD
- RECRUITINGNCT02257866Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic VasculitisNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · PI: Peter C Grayson, M.D.